[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol; 2004 Mar 1;22(5):890-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
  • PURPOSE: A multicenter phase II study evaluating efficacy, safety, and pharmacokinetics of ecteinascidin-743 (ET-743) in pretreated advanced soft tissue sarcoma patients.
  • PATIENTS AND METHODS: Patients received ET-743 1,500 microg/m(2) (24-hour intravenous infusion) every 3 weeks (group 1, 26 patients with one to two prior single agents or one previous combination chemotherapy; group 2, 28 patients with three or more prior single agents or two or more previous combination chemotherapies).
  • Results Patients (30 women, 24 men) had a median age of 48 years (range, 22 to 71 years); 41% had leiomyosarcoma (eight of 22 of uterine origin), a median of two involved organs (range, one to four), and 93% had documented progressive disease at study entry.
  • Four patients withdrew because of treatment-related toxicity.
  • Two treatment-related deaths occurred (renal failure and febrile neutropenia, and rhabdomyolysis and decompensated cirrhosis, respectively) that were probably related to protocol eligibility violations.
  • CONCLUSION: With a 4% overall response rate (95% CI, 0.5 to 12.8) and an 11% rate of third-party-verified tumor regression (overall response rate + minor response), ET-743 has a 24% 6-month disease progression control rate, confirming evidence of antitumoral activity and a manageable safety profile in patients experiencing disease progression with pretreated soft tissue sarcoma.
  • [MeSH-major] Dioxoles / administration & dosage. Isoquinolines / administration & dosage. Salvage Therapy. Sarcoma / drug therapy. Sarcoma / pathology. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biological Availability. Biopsy, Needle. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Probability. Survival Analysis. Tetrahydroisoquinolines. Treatment Outcome


2. Basche M, Gustafson DL, Holden SN, O'Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG: A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res; 2006 Sep 15;12(18):5471-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
  • Other toxicity was generally mild and included prolongation of the activated partial thromboplastin time and injection site echymosis.
  • Both AUC and C(max) correlated with the percent increase in activated partial thromboplastin time, showing that this pharmacodynamic end point can be used as a surrogate for drug exposure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Glucuronidase / antagonists & inhibitors. Neoplasms / drug therapy. Oligosaccharides / therapeutic use
  • [MeSH-minor] Adult. Aged. Antibody Formation / drug effects. Carcinoid Tumor / drug therapy. Carcinoma, Renal Cell / drug therapy. Colorectal Neoplasms / drug therapy. Female. Fibroblast Growth Factors / blood. Humans. Leiomyosarcoma / drug therapy. Male. Maximum Tolerated Dose. Melanoma / drug therapy. Middle Aged. Partial Thromboplastin Time. Vascular Endothelial Growth Factor A / blood


3. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP: Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med; 2008 May 06;6:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors.
  • The heterogeneity that soft tissue sarcomas (STS) exhibit in their clinical behavior, even within histological subtypes, complicates patient care.
  • Morphologic features are generally good predictors of biologic behavior, however, metastatic propensity, tumor growth, and response to chemotherapy may be determined by gene expression patterns that do not correlate well with morphology.
  • We have reported gene expression patterns that distinguish two subgroups of clear cell renal carcinoma (ccRCC), and other gene expression patterns that distinguish heterogeneity of serous ovarian carcinoma (OVCA) and aggressive fibromatosis (AF).
  • In this study, gene expression in 53 samples of STS and AF [including 16 malignant fibrous histiocytoma (MFH), 9 leiomyosarcoma, 12 liposarcoma, 4 synovial sarcoma, and 12 samples of AF] was determined at Gene Logic Inc. (Gaithersburg, MD) using Affymetrix GeneChip U_133 arrays containing approximately 40,000 genes/ESTs.
  • In addition, several genes that are targets of some anti-tumor drugs were found to be differentially expressed in particular subsets of STS.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] J Lab Clin Med. 2004 Aug;144(2):78-91 [15322502.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):994-8 [3409180.001]
  • [Cites] Am J Physiol. 1992 Dec;263(6 Pt 1):L627-33 [1476204.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:101-11 [1309029.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):705-10 [8539226.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):329-34 [9250146.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):77-82 [10518103.001]
  • [Cites] Cancer Immun. 2005 Feb 1;5:2 [15683221.001]
  • [Cites] Cancer Invest. 2005;23(2):105-18 [15813502.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Histopathology. 2006 Jan;48(1):22-31 [16359534.001]
  • [Cites] Histopathology. 2006 Jan;48(1):51-62 [16359537.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] J Lab Clin Med. 2006 May;147(5):250-67 [16697773.001]
  • [Cites] Transl Res. 2006 Nov;148(5):223-48 [17145569.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):364-99 [17442230.001]
  • [Cites] Mayo Clin Proc. 2007 Nov;82(11):1409-32 [17976362.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):514-27 [18068629.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6615-20 [10597266.001]
  • [Cites] J Clin Pathol. 1999 Sep;52(9):695-6 [10655994.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Int J Cancer. 2001 Mar 20;95(2):102-7 [11241320.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Breast Cancer Res. 2001;3(6):365-72 [11737887.001]
  • [Cites] Lab Invest. 2002 Jan;82(1):97-103 [11796830.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):39-46 [11823972.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]
  • [Cites] J Lab Clin Med. 2003 May;141(5):297-308 [12761473.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1029-38 [12942572.001]
  • [Cites] J Lab Clin Med. 2004 Feb;143(2):89-98 [14966464.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4776-83 [15269152.001]
  • [Cites] Cancer Immun. 2004 Aug 9;4:7 [15298487.001]
  • [Cites] J Clin Invest. 1985 Jan;75(1):11-8 [3965498.001]
  • (PMID = 18460215.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-03; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-03; United States / NCI NIH HHS / CA / R01CA106878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2412854
  •  go-up   go-down


Advertisement
4. Gallup DG, Blessing JA, Andersen W, Morgan MA, Gynecologic Oncology Group Study: Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol; 2003 Apr;89(1):48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study.
  • OBJECTIVE: The purpose of this phase II trial was to evaluate the efficacy of intravenous paclitaxel in patients with recurrent or advanced leiomyosarcoma of the uterus.
  • METHODS: To be eligible, patients with recurrent or persistent leiomyosarcoma of the uterus were to have measurable disease not previously treated with paclitaxel and adequate hematologic (WBC >or=3000/microl, platelet count >or=100000/microl), renal (serum creatinine <or=2.0 mg%), and hepatic (bilirubin <or= 1.5 x institutional normal) functions.
  • Fifteen had prior irradiation and 39 had prior chemotherapy.
  • No grade 4 thrombocytopenia was reported and no deaths were attributable to therapy.
  • CONCLUSIONS: Although toxicity was minimal, this regimen demonstrated modest activity in patients with previously treated advanced or recurrent leiomyosarcoma of the uterus.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Leiomyosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / therapeutic use. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694653.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA27469; United States / NCI NIH HHS / CA / CA37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Dew J, Hansen K, Hammon J, McCoy T, Levine EA, Shen P: Leiomyosarcoma of the inferior vena cava: surgical management and clinical results. Am Surg; 2005 Jun;71(6):497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the inferior vena cava: surgical management and clinical results.
  • Leiomyosarcoma of the inferior vena cava (IVC) is a rare lesion with less than 300 cases reported.
  • From August 1984 to June 2004, eight patients with leiomyosarcoma of the IVC were treated at our institution.
  • Tumor location was between the renal and iliac veins (low) (n = 4, 50%), between the hepatic and renal veins (middle) (n = 3, 38%), and above the hepatic veins with right atrial extension (high) (n = 1, 12%).
  • Postoperative morbidity included deep venous thrombosis (DVT) (n = 1), lower extremity edema (mild n = 1; moderate n = 1), GI bleed (n = 1), and chronic renal insufficiency (n = 1).
  • One patient is currently receiving adjuvant chemotherapy.
  • Four patients received chemotherapy after recurrence, and one received palliative radiation therapy as well.
  • The type of IVC reconstruction had no effect on survival (P = 0.22).
  • Recurrence was discovered in four patients (50%) at a median time of 14 months.
  • Resection of leiomyosarcoma of the IVC should be attempted whenever feasible.
  • [MeSH-major] Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Vascular Neoplasms / pathology. Vascular Neoplasms / surgery. Vena Cava, Inferior
  • [MeSH-minor] Adult. Aged. Blood Vessel Prosthesis Implantation / methods. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Vascular Surgical Procedures / methods

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044929.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Edmonson JH, Blessing JA, Cosin JA, Miller DS, Cohn DE, Rotmensch J: Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol; 2002 Jun;85(3):507-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study.
  • OBJECTIVE: Because of preliminary observations favoring the use of mitomycin, doxorubicin, and cisplatin (MAP) chemotherapy in leiomyosarcomas, the Gynecologic Oncology Group (GOG) decided to conduct a phase II clinical trial of this combination regimen in patients with advanced disease.
  • METHODS: Patients with histologically confirmed uterine leiomyosarcoma who had not previously received cytotoxic drugs were considered for participation in this clinical trial.
  • Eligible patients had measurable disease, GOG performance status 0-2, and adequate bone marrow, renal, and hepatic function according to standard criteria.
  • RESULTS: Forty-one patients were registered, of whom 4 were determined ineligible (wrong cell type, 2; wrong site of origin, 1; inadequate pathology material, 1).
  • Despite its low therapeutic index, this novel, possibly interactive, combination may serve as a forerunner to regimens that more efficiently exploit the enhancement of sarcoma cell kill under hypoxic conditions.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leiomyosarcoma / drug therapy. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12051882.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; MAP protocol
  •  go-up   go-down


7. Asavamongkolkul A, Waikakul S, Phimolsarnti R, Kiatisevi P, Wangsaturaka P: Endoprosthetic reconstruction for malignant bone and soft-tissue tumors. J Med Assoc Thai; 2007 Apr;90(4):706-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoprosthetic reconstruction for malignant bone and soft-tissue tumors.
  • BACKGROUND: Nowadays, the results of the management of malignant bone and soft-tissue tumors have been dramatically improved because of the advance in imaging, chemotherapy, radiation therapy, and surgical techniques.
  • Patients can have longer survival times with limb-salvage surgery.
  • OBJECTIVE: To report the preliminary results of 32 endoprosthetic reconstructions following malignant bone and soft-tissue tumor resection.
  • MATERIAL AND METHOD: Since September 1988, the authors have performed 188 limb-salvage surgical operations for the treatment of musculoskeletal tumors at Siriraj Hospital.
  • From March 1994 to July 2006, 32 endoprosthetic reconstructions were performed on 30 patients following malignant bone or soft-tissue tumor removal.
  • The diagnosis was conventional osteosarcoma in 16 patients, parosteal osteosarcoma in two patients, chondrosarcoma in two patients, leiomyosarcoma in two patients, failed allograft in two patients and one patient each of periosteal osteosarcoma, Ewing's sarcoma, Gorham's disease, synovial sarcoma, malignant fibrous histiocytoma, metastatic renal cell carcinoma, and prosthetic loosening.
  • Five proximal femurs, 17 distal femurs, 1 total femur 3 proximal tibias, 1 intercalary tibia, 4 proximal humerus and 1 distal humerus were used for reconstruction.
  • RESULTS: The mean follow-up time was 26 months (range 6-128.7).
  • CONCLUSION: Endoprosthetic reconstruction could yield satisfactory results as a wide excision and limb-salvage for patients with malignant bone and soft-tissue tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage. Osteosarcoma / surgery. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487125.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


8. Kwon TW, Sung KB, Cho YP, Kim DK, Yang SM, Ro JY, Kim GE: Pararenal leiomyosarcoma of the inferior vena cava. J Korean Med Sci; 2003 Jun;18(3):355-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pararenal leiomyosarcoma of the inferior vena cava.
  • A complete surgical resection is the only proven therapeutic modality that prolongs the survival in patients with leiomyosarcoma of the inferior vena cava (IVC).
  • Reconstruction of the IVC is not always necessary but is often required to facilitate venous drainage of the kidney for the tumors at the pararenal area of the IVC.
  • Controversy exists in postoperative adjuvant therapy.
  • Recently, we experienced four cases of pararenal leiomyosarcoma of the IVC, of which treatment consisted of a complete resection of the tumor, ringed polytetrafluoroethylene (PTFE) graft interposition, and bilateral renal vein reconstructions in all patients.
  • Postoperative radiation therapy was instituted in 3 of 4 patients.
  • One patient who did not receive the postoperative radiation therapy was treated with adjuvant chemotherapy.
  • The kidneys were preserved in all patients and no deep vein thrombosis (DVT) or venous insufficiency of the lower extremity veins developed.
  • Distant metastasis to the lung was noted in one patient at 18 months after surgery, who was not received the postoperative radiation therapy but chemotherapy.
  • In conclusion, a complete resection of the tumor, IVC reconstruction, and bilateral renal vein reconstruction followed by adjuvant radiation therapy is recommended for the treatment of pararenal leiomyosarcoma of the IVC.
  • [MeSH-major] Leiomyosarcoma / radiotherapy. Leiomyosarcoma / surgery. Vascular Neoplasms / radiotherapy. Vascular Neoplasms / surgery. Vena Cava, Inferior
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Retroperitoneal Neoplasms / radiography. Retroperitoneal Neoplasms / radiotherapy. Retroperitoneal Neoplasms / surgery. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12808321.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3055040
  •  go-up   go-down


9. Bonnet S, Eggenspieler P, Vedrine L, Camparo P, Baranger B: [Leiomyosarcoma of the middle segment of the inferior vena cava: tactical problems raised by renal and caval revascularisation]. J Mal Vasc; 2006 May;31(2):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leiomyosarcoma of the middle segment of the inferior vena cava: tactical problems raised by renal and caval revascularisation].
  • [Transliterated title] Léiomyosarcome du segment moyen de la veine cave inférieure: problèmes tactiques soulevés par la revascularisation cave et rénale.
  • INTRODUCTION: Leiomyosarcoma of the inferior vena cava is mesenchymal tumor accounting for 95% of primary tumors of the vena cava.
  • Characteristic features include late invasion of adjacent structures and metastases, and delayed diagnosis.
  • OBSERVATION: We report a case of inferior vena cava (IVC) leiomyosarcoma (LMS) found in a 53 year-old man who complained of abdominal pain.
  • Morphologic exams found a very large polycyclic mass in the inferior vena cava involving the middle segment of the vena cava extending from the renal veins to the hepatic veins.
  • Caval outflow was restored using a ring-reinforced PTFE tube graft, the left renal vein was ligated and not re-implanted, the right renal vein was implanted in a lumbar sub-renal vein using a short prosthesis.
  • Pathological examination documented a grade II leiomyosarcoma of the inferior vena cava and the patient was given adjuvant chemotherapy (anthracycline).
  • Furthermore, the importance of restoring right renal outflow is highlighted because ligature of the renal vein can lead to renal ischemia and nephrectomy which should only be performed in specific cases.
  • The tactical problems of renal and caval revascularisation, including the place of prosthetic replacement, are discussed.
  • [MeSH-major] Kidney / blood supply. Leiomyosarcoma / diagnosis. Vascular Neoplasms / diagnosis. Vena Cava, Inferior / surgery
  • [MeSH-minor] Blood Vessel Prosthesis. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Renal Veins / surgery

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733439.001).
  • [ISSN] 0398-0499
  • [Journal-full-title] Journal des maladies vasculaires
  • [ISO-abbreviation] J Mal Vasc
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Dominici A, Mondaini N, Nesi G, Travaglini F, Di Cello V, Rizzo M: Cystic leiomyosarcoma of the kidney: an unusual clinical presentation. Urol Int; 2000;65(4):229-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic leiomyosarcoma of the kidney: an unusual clinical presentation.
  • Primary sarcomas of the kidney are rare, accounting for 1-3% of all renal malignancies.
  • We describe an unusual case of renal leiomyosarcoma in a 41-year-old white woman who presented with a large smooth mass, which was mobile to the overlying structures and which occupied the right hypochondria and flank.
  • Leiomyosarcomas of the kidney have an aggressive and rapidly progressive natural history, with 5-year survival rates of 29-36%.
  • Size <5 cm, low histological grade, absence of lymph node metastases and radical surgical treatment are all associated with a better prognosis.
  • Irradiation and chemotherapy do not appear to alter the clinical course.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / surgery. Leiomyosarcoma / diagnosis. Leiomyosarcoma / surgery
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Follow-Up Studies. Humans. Nephrectomy / methods. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 11112879.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


11. Cautero N, De Luca S, Vecchi A, Garelli P, Nicolini D, Martorelli G, Frascà GM, Gaffi G, Taruscia D, Bearzi I, Adani G, Risaliti A: Peritoneal leiomyosarcoma in a kidney transplant patient: a case report. Transplant Proc; 2007 Jul-Aug;39(6):2038-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal leiomyosarcoma in a kidney transplant patient: a case report.
  • Our present report focused on a 46-year-old woman who received immunosuppressive therapy based on cyclosporine and steroids for renal transplantation.
  • Eight years after transplantations, she suffered lower abdominal pain and a mass involving peritoneal soft tissues was located near the right iliac vessels.
  • Upon radical tumor excision, the histological examination revealed a high-grade leiomyosarcoma.
  • After 30 days, a computed tomography scan revealed two small pulmonary metastases, so the patient received adriamycin.
  • Six months after the diagnosis, there was no intra-abdominal relapse and the pulmonary metastasis remain stable.
  • The function of the transplanted kidney was normal and the patient was listed for laparoscopic pulmonary resection.
  • Sarcomas in solid organ transplant patients appear to have aggressive features with 62% being high grade and 40% metastatic at the time of primary diagnosis with a recurrence rate of 30% and a 5-year survival rate of 25%.
  • Patients diagnosed with sarcoma should be treated with multimodality therapy.
  • After aggressive surgery whenever possible, a combination of a traditional cytotoxic drug and a "signal" blocking agent like rapamycin may increase selectivity toward tumor cells.
  • [MeSH-major] Kidney Transplantation. Leiomyosarcoma / diagnosis. Peritoneal Neoplasms / diagnosis. Sirolimus / therapeutic use
  • [MeSH-minor] Female. Humans. Immunosuppressive Agents / therapeutic use. Lung Neoplasms / pathology. Middle Aged. Neoplasm Metastasis. Postoperative Complications / diagnosis. Postoperative Complications / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692686.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


12. Check JH, Dix E, Cohen R, Check D, Wilson C: Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res; 2010 Feb;30(2):623-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types.
  • The present study evaluated the palliative effect of mifepristone in a variety of different types of human cancer.
  • PATIENTS AND METHODS: Mifepristone was given at 200 mg daily orally with permission from the Food and Drug Administration to people with widely metastatic human cancer no longer responsive to other chemotherapy regimens.
  • RESULTS: Improvement in pain and energy and/or length of life was found in thymic epithelial cell carcinoma, transitional cell carcinoma of the renal pelvis, leiomyosarcoma, pancreatic carcinoma, malignant fibrous histiocytoma and another case of adenocarcinoma of the colon.
  • CONCLUSION: Our data demonstrate a palliative role for the use of mifepristone in cancer therapy.
  • Progesterone receptor antagonists should be given a therapeutic trial in larger controlled studies of various malignancies in humans.
  • [MeSH-major] Hormone Antagonists / therapeutic use. Mifepristone / therapeutic use. Neoplasms / drug therapy. Palliative Care. Receptors, Progesterone / antagonists & inhibitors
  • [MeSH-minor] Adult. Aged. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / secondary. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Female. Histiocytoma, Malignant Fibrous / drug therapy. Histiocytoma, Malignant Fibrous / pathology. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Leiomyosarcoma / drug therapy. Leiomyosarcoma / secondary. Male. Middle Aged. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Survival Rate. Thymus Neoplasms / drug therapy. Thymus Neoplasms / pathology. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20332480.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hormone Antagonists; 0 / Receptors, Progesterone; 320T6RNW1F / Mifepristone
  •  go-up   go-down


13. Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, van Oosterom A, Radford JA, Svancárová L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW, Verweij J: Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer; 2000 Jan;36(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
  • In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m2 repeated every 4 weeks with adequate mesna protection and hydration was evaluated in patients with advanced soft tissue sarcomas.
  • HDI was given both as first-line and second-line chemotherapy.
  • The predominant histology was leiomyosarcoma (33%).
  • At the time of analysis 55 patients have died.
  • The median time to progression was 15 weeks.
  • The major grade 3 + 4 non-haematological toxicities encountered were febrile neutropenia in 39%, infection in 20%, and acute renal failure in 4%.
  • HDI given as a continuous infusion at this dose cannot be recommended as the standard treatment of advanced soft tissue sarcomas, even in selected patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Ifosfamide / administration & dosage. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741296.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


14. Smith HO, Blessing JA, Vaccarello L: Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2002 Jan;84(1):140-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
  • OBJECTIVE: This study was conducted to determine the objective response of trimetrexate in patients with advanced or recurrent leiomyosarcoma of the uterus.
  • METHODS: Eligibility was restricted to patients with measurable disease who had received no more than one prior chemotherapy regimen, who had adequate bone marrow, renal, and hepatic function, and who had recovered from previous therapy.
  • Prior therapy included radiation (7 patients) and/or chemotherapy (10 patients).
  • Toxicities were mild to moderate with no treatment-related deaths.
  • CONCLUSION: Although toxicity is acceptable, trimetrexate at this dose and schedule is ineffective therapy for patients with recurrent leiomyosarcoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Leiomyosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Trimetrexate / therapeutic use. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Administration Schedule. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRIMETREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11748990.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; UPN4ITI8T4 / Trimetrexate
  •  go-up   go-down


15. Kyriazi MA, Stafyla VK, Chatzinikolaou I, Koureas A, Chatziioannou A, Kondi-Paphiti A, Arkadopoulos N, Smyrniotis V: Surgical challenges in the treatment of leiomyosarcoma of the inferior vena cava: analysis of two cases and brief review of the literature. Ann Vasc Surg; 2010 Aug;24(6):826.e13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical challenges in the treatment of leiomyosarcoma of the inferior vena cava: analysis of two cases and brief review of the literature.
  • BACKGROUND: Leiomyosarcoma of the inferior vena cava (IVC) is a rare tumor of mesenchymal origin.
  • Optimal treatment should include complete resection of the malignant lesion with preservation of venous return.
  • METHODS AND RESULTS: The first case is that of a 54-year-old woman, with a 9 cm a primary IVC leiomyosarcoma extending from the level of the right renal vein to the common iliac veins.
  • She received adjuvant chemotherapy and is free of recurrence almost 3 years after surgery.
  • The second case is that of a 56-year-old woman presenting with back pain due to an 8-cm retroperitoneal mass in close proximity to the right renal vein.
  • Pathological examination confirmed primary leiomyosarcoma of the IVC.
  • She received adjuvant chemotherapy, but was referred to our hospital with local recurrence 6 months after the operation and is suffering from disseminated abdominal disease almost a year postsurgery.
  • CONCLUSION: Radical surgical en bloc resection is the mainstay of treatment for IVC leiomyosarcomas.
  • [MeSH-major] Leiomyosarcoma / surgery. Vascular Neoplasms / surgery. Vascular Surgical Procedures. Vena Cava, Inferior / surgery
  • [MeSH-minor] Abdominal Pain / etiology. Back Pain / etiology. Chemotherapy, Adjuvant. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20471215.001).
  • [ISSN] 1615-5947
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


16. Singh I, Joshi M, Mishra K: Capsular renal leiomyosarcoma with encasement of the inferior vena cava - Diagnosed by immunostaining and review of literature. Urol Ann; 2010 Jan;2(1):36-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capsular renal leiomyosarcoma with encasement of the inferior vena cava - Diagnosed by immunostaining and review of literature.
  • We report and describe the presentation, pathological diagnosis with immunostaining and management of a rare case of capsular renal leiomyosarcoma encasing the inferior vena cava (IVC).
  • The present case was successfully managed by radical nephrectomy and adjuvant radio-chemotherapy.
  • Immunostaining should be freely used to define the histological type of renal sarcoma in order to accurately counsel and deliver a prognosis for patients with renal leiomyosarcomas with a poor prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842257.001).
  • [ISSN] 0974-7834
  • [Journal-full-title] Urology annals
  • [ISO-abbreviation] Urol Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2934590
  • [Keywords] NOTNLM ; Renal leiomyosarcoma / renal pelvic sarcoma / renal sarcoma
  •  go-up   go-down


17. Hilliard NJ, Heslin MJ, Castro CY: Leiomyosarcoma of the inferior vena cava: three case reports and review of the literature. Ann Diagn Pathol; 2005 Oct;9(5):259-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the inferior vena cava: three case reports and review of the literature.
  • We describe 3 cases of leiomyosarcoma of the inferior vena cava (IVC) and review the literature describing clinicopathologic features of 211 cases and the outcome.
  • Of all patients, 47% underwent complete resection, 24% had complete resection with preoperative or postoperative chemotherapy and/or radiation, and 5% had palliative surgery.
  • Although there is no standardized criteria for the grading of extrauterine leiomyosarcoma, we propose to grade based on mitotic activity as follows: high grade, 10 or more mitoses per 10 high-power field (HPF); intermediate grade, 5 to 9 mitoses per 10 HPF; and low grade, 1 to 4 mitoses per 10 HPF.
  • [MeSH-major] Leiomyosarcoma / pathology. Leiomyosarcoma / physiopathology. Vascular Neoplasms / pathology. Vascular Neoplasms / physiopathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Aged. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Female. Hemangiosarcoma / pathology. Humans. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / surgery. Sarcoma / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198953.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Barakat RK, Singh N, Lal R, Verani RR, Finkel KW, Foringer JR: Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother; 2007 Apr;41(4):707-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma.
  • CASE SUMMARY: A 26-year-old man diagnosed with metastatic rectal leiomyosarcoma was treated with intravenous bevacizumab 5 mg/kg and received a total of 3 doses at 2 week intervals.
  • Acute renal failure was diagnosed, and hemodialysis was initiated.
  • A renal biopsy revealed interstitial nephritis.
  • Renal failure resolved with cessation of the drug, and the patient did not require further hemodialysis.
  • Bevacizumab has shown efficacy in treatment of patients with renal cell carcinoma and colorectal cancer and has been approved by the Food and Drug Administration as a first-line treatment for metastatic colorectal cancer.
  • Our patient had no other confounding factors that might have caused renal failure.
  • According to the Naranjo probability scale, bevacizumab was the probable cause of acute renal failure in this patient.
  • CONCLUSIONS: Bevacizumab can cause acute renal failure by inducing interstitial nephritis.
  • Renal function should be monitored during bevacizumab therapy.
  • [MeSH-major] Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal / adverse effects. Leiomyosarcoma / drug therapy. Nephritis, Interstitial / chemically induced. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374619.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab; AYI8EX34EU / Creatinine
  •  go-up   go-down


19. Dhall D, Al-Ahmadie HA, Dhall G, Shen-Schwarz S, Tickoo SK: Pediatric renal cell carcinoma with oncocytoid features occurring in a child after chemotherapy for cardiac leiomyosarcoma. Urology; 2007 Jul;70(1):178.e13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric renal cell carcinoma with oncocytoid features occurring in a child after chemotherapy for cardiac leiomyosarcoma.
  • We report a case of renal cell carcinoma (RCC) with extensive oncocytoid features developing in a 12-year-old African-American boy after chemotherapy for cardiac leiomyosarcoma at 3 months of age.
  • The tumor showed histopathologic features similar to those previously reported in RCC after chemotherapy for neuroblastoma and now considered a specific entity in the World Health Organization classification of renal tumors as "RCC associated with neuroblastoma."
  • Our report expands the spectrum of tumors (beyond neuroblastoma) in which RCCs with such an appearance can arise in the pediatric age group after chemotherapy.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Heart Neoplasms / drug therapy. Kidney Neoplasms / pathology. Leiomyosarcoma / drug therapy. Neoplasms, Second Primary / pathology


20. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G: A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res; 2004 Nov 15;10(22):7450-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early clinical trials were limited because of dose-limiting gastrointestinal toxicity, and parenteral dosing of this class of agents is not possible because of their hemolytic properties; therefore, related compounds with an improved therapeutic index were developed.
  • No treatment related deaths occurred.
  • Pharmacokinetic data confirmed the maintenance of stable drug levels with chronic dosing and the long half-life.
  • These results suggest perifosine activity in sarcoma and perhaps renal cell carcinoma (stable disease in two patients who continued for 6 and 14 courses), thus justifying additional investigation of this agent in a phase II sarcoma trial.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15569974.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / U01 CA62491
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Serotonin 5-HT3 Receptor Antagonists; 107-73-3 / Phosphorylcholine; 2GWV496552 / perifosine; 6X9OC3H4II / Loperamide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


21. Mohanty SK, Balani JP, Parwani AV: Pleomorphic leiomyosarcoma of the adrenal gland: case report and review of the literature. Urology; 2007 Sep;70(3):591.e5-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic leiomyosarcoma of the adrenal gland: case report and review of the literature.
  • Computed tomography showed a large heterogeneous left adrenal mass abutting the renal vessels.
  • The adrenal mass was resected and histopathologic examination revealed a highly pleomorphic malignant spindle cell neoplasm diffusely infiltrating the adrenal parenchyma with an immunoprofile consistent with that of a leiomyosarcoma.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Leiomyosarcoma / pathology
  • [MeSH-minor] Abdominal Pain / etiology. Adrenalectomy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Leiomyoma / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Middle Aged. Neoplasms, Second Primary / pathology. Nephrectomy. Radiotherapy, Adjuvant. Taxoids / administration & dosage. Thrombophlebitis / etiology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905130.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 14
  •  go-up   go-down


22. Sutton G, Blessing J, Hanjani P, Kramer P, Gynecologic Oncology Group: Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol; 2005 Mar;96(3):749-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
  • OBJECTIVE: This is a phase II group-wide study of liposomal doxorubicin chemotherapy in patients with advanced or recurrent uterine leiomyosarcomas.
  • METHODS: Patients with histologically confirmed persistent or recurrent leiomyosarcomas of the uterus with documented disease progression after appropriate local therapy were invited to participate in this study.
  • Bidimensionally measurable disease, GOG performance status of 0, 1, or 2 (Karnofsky 80-100) was required; all patients must have failed local therapeutic measures and be considered incurable.
  • Other eligibility criteria included adequate hepatic, renal, and hematologic function.
  • Patients were ineligible if they had received previous chemotherapy or had other noncutaneous malignancies.
  • Three patients were determined ineligible because of wrong pathological cell type or inadequate pathology information and one was inevaluable for lack of data.
  • Two patients developed grade 3 and one patient developed grade 4 cardiovascular adverse events, not necessarily drug related.
  • There were seven cases of grade 3 or 4 gastrointestinal toxicity and two patients developed grade 3 dermatologic toxicity.
  • CONCLUSION: The dose and schedule of liposomal doxorubicin employed in this trial showed no advantage over historical results with doxorubicin in the treatment of uterine leiomyosarcoma.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Doxorubicin / therapeutic use. Leiomyosarcoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721421.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


23. Kadikoy H, Haque WM, Topkara VK, Frome AI, Hayes TG: Bilateral leiomyosarcoma of the kidney with family history of kidney cancer. Can J Urol; 2009 Oct;16(5):4847-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral leiomyosarcoma of the kidney with family history of kidney cancer.
  • Sarcomas make up 1%-2% of all malignant renal tumors in adults, and the incidence increases with advancing age.
  • Renal sarcomas are less common, but more lethal than sarcomas of any other genitourinary site.
  • The common clinical presentation of renal sarcomas in adults include a palpable mass, abdominal or flank pain, and hematuria, similar to those seen with large, rapidly growing renal cell carcinomas.
  • Usually, radical nephrectomy remains the treatment of choice for these tumors, which exhibit an aggressive biological behavior and an unfavorable prognosis.
  • We describe an unusual case of bilateral renal leiomyosarcoma in a 61-year-old white male.
  • The patient also had an uncle who had bilateral kidney cancer.
  • In addition, our patient presented with a pulmonary embolism, which is different from the classic presentation of leiomyosarcoma.
  • He was treated with gemcitabine and docetaxel chemotherapy, with stabilization of disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Genetic Predisposition to Disease. Immunotherapy / methods. Kidney Neoplasms / diagnosis. Leiomyosarcoma / diagnosis. Nephrectomy / methods
  • [MeSH-minor] Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed


24. Daylami R, Amiri A, Goldsmith B, Troppmann C, Schneider PD, Khatri VP: Inferior vena cava leiomyosarcoma: is reconstruction necessary after resection? J Am Coll Surg; 2010 Feb;210(2):185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inferior vena cava leiomyosarcoma: is reconstruction necessary after resection?
  • BACKGROUND: Leiomyosarcomas of the inferior vena cava represent a rare form of soft-tissue sarcomas.
  • Questions about necessity of multimodality therapy and IVC reconstruction remain.
  • Lower-extremity edema developed in 3 patients (50%), but this was well tolerated and did not lead to any long-term sequelae.
  • Pulmonary metastasis developed postoperatively in 1 patient (17%) and was successfully treated with chemotherapy and metastectomy.
  • Acute renal failure developed in 3 patients, but all recovered full function.
  • Chylous leak developed in 2 patients (34%).
  • CONCLUSIONS: Leiomyosarcoma of the IVC is a treatable malignancy.
  • Acute renal failure can be a common, albeit transient, early postoperative complication.
  • [MeSH-major] Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Vascular Neoplasms / pathology. Vascular Neoplasms / surgery. Vena Cava, Inferior
  • [MeSH-minor] Adrenalectomy. Aged. Aged, 80 and over. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Nephrectomy. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Coll Surg. 2010 Jul;211(1):145-6 [20610268.001]
  • (PMID = 20113938.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Chuman H: [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma]. Gan To Kagaku Ryoho; 2003 May;30(5):626-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current topics in the diagnosis and treatment of malignant fibrous histiocytoma].
  • MFH-like histological changes are observed in many bone and cartilage sarcomas, and some renal cell carcinomas and malignant lymphomas.
  • These changes occur in many subtypes of sarcomas such as osteogenic sarcoma, chondrosarcoma, leiomyosarcoma, rhabdomyosarcoma, and liposarcoma.
  • Patients with MFH often have repeated recurrences before a diagnosis is made, and the tumor is partially resected.
  • The sensitivity of MFH to radiotherapy and chemotherapy is insufficient, and evidence is lacking for adjuvant treatment.
  • Rescue following initial treatment failure is extremely difficult.
  • Local control of 70% to 90% can be achieved if a correct diagnosis is made, and a curative wide resection or salvage wide resection are done early.
  • For treatment of bone and soft tissue sarcoma, a correct diagnosis and initial treatment are extremely important.
  • Many cases need to be accumulated in joint clinical studies across fields according to organ and specialty, and effective treatment method developed.
  • We need to advance the standardization of treatment for MFH, and eliminate wrong initial treatment through the active provision of information.
  • [MeSH-major] Bone Neoplasms. Histiocytoma, Benign Fibrous. Soft Tissue Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Prognosis. Radiotherapy, Adjuvant. Sarcoma / pathology. Sarcoma / surgery. Sarcoma / therapy. Survival Rate

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12795093.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Serrone L, Zeuli M, Gamucci T, Nardi M, Cognetti F: A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Cancer Chemother Pharmacol; 2001 Mar;47(3):206-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
  • PURPOSE: The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS).
  • METHODS: Since November 1995, 22 chemotherapy-naive patients have been treated.
  • G-CSF was planned for each course of treatment as a daily subcutaneous injection for 7 days, starting 24 h after the end of the treatment.
  • After the first four cycles, patients were evaluated for surgery and patients with locally inoperable or metastatic disease received further chemotherapy up to a maximum of eight cycles.
  • Noteworthy is that two of the six leiomyosarcoma patients responded to the HD-IFO treatment.
  • No severe renal and CNS toxicities were seen.
  • Transient gross hematuria occurred in six patients and affected treatment in only one case.
  • There were no treatment-related deaths.
  • CONCLUSIONS: By the protraction of continuous infusion of HD-IFO over 6 to 8 days, ifosfamide-induced acute renal toxicity is avoided, while G-CSF support allows the delivery of the planned dose intensity in most of the patients.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Epirubicin / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Ifosfamide / administration & dosage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11320663.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


27. Senderowicz AM: Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia; 2001 Jan;15(1):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
  • Initial clinical trials with infusional flavopiridol demonstrated activity in some patients with non-Hodgkin's lymphoma, renal, prostate, colon and gastric carcinomas.
  • The first clinical trial of UCN-01 demonstrated very prolonged half-life (approximately 600 h), 100 times longer than the half-life observed in preclinical models.
  • Clinical activity was observed in patients with melanoma, non-Hodgkin's lymphoma and leiomyosarcoma.
  • Of interest, a patient with anaplastic large cell lymphoma refractory to high-dose chemotherapy showed no evidence of disease after 3 years of UCN-01 therapy.
  • Although important questions remain to be answered, these positive experiences will hopefully increase the therapeutic modalities in hematological malignancies.
  • [MeSH-major] Alkaloids / pharmacology. Cyclin-Dependent Kinases / antagonists & inhibitors. Enzyme Inhibitors / pharmacology. Flavonoids / pharmacology. Hematologic Neoplasms / drug therapy. Piperidines / pharmacology
  • [MeSH-minor] Cell Cycle / drug effects. Clinical Trials as Topic. Humans. Retinoblastoma Protein / metabolism. Signal Transduction / drug effects. Staurosporine / analogs & derivatives

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11243375.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Piperidines; 0 / Retinoblastoma Protein; 45AD6X575G / alvocidib; 7BU5H4V94A / 7-hydroxystaurosporine; EC 2.7.11.22 / Cyclin-Dependent Kinases; H88EPA0A3N / Staurosporine
  • [Number-of-references] 100
  •  go-up   go-down


28. Sharma D, Pradhan S, Aryya NC, Shukla VK: Leiomyosarcoma of kidney: a case report with long term result after radiotherapy and chemotherapy. Int Urol Nephrol; 2007;39(2):397-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of kidney: a case report with long term result after radiotherapy and chemotherapy.
  • Leiomyosarcoma of the kidney is a rare entity with poor prognosis.
  • Among renal sarcomas, it is the most common histologic subtype amounting to 50-60% of all cases.
  • The tumors usually arise from either the renal capsule or smooth muscle tissue in the renal pelvic wall.
  • We describe a case of renal leiomyosarcoma that presented with history of left flank pain.
  • Abdominal ultrasound showed a solid lesion of 38 x 36 mm arising from the left kidney.
  • Intravenous urography showed cut off of both major and minor calyces of the left kidney from its pelvis with a normal right kidney.
  • Exploratory laparotomy revealed a well-encapsulated mass confined to the renal parenchyma for which radical nephrectomy was performed.
  • Histopathology showed a Grade I leiomyosarcoma arising from the renal capsule.
  • Adjuvant chemotherapy and sandwich radiotherapy was given and he is disease free after six and half years of follow up.
  • The rarity of this disease, its severity and poor prognosis, uncommon form of presentation, resulting delay in diagnosis and difficulty in management is highlighted and reported.
  • [MeSH-major] Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiotherapy. Leiomyosarcoma / drug therapy. Leiomyosarcoma / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Urol. 2002 Nov 19;2:13 [12441005.001]
  • [Cites] Arkh Patol. 1986;48(4):70-2 [3718269.001]
  • [Cites] Scand J Urol Nephrol. 2001 Oct;35(5):425-7 [11771874.001]
  • [Cites] Klin Padiatr. 1975 Jul;187(4):361-6 [1172161.001]
  • [Cites] Urol Int. 2000;65(4):229-31 [11112879.001]
  • [Cites] Arch Esp Urol. 2004 Oct;57(8):870-2 [15560282.001]
  • [Cites] Pediatr Radiol. 1997 Jun;27(6):557-8 [9174033.001]
  • [Cites] World J Surg Oncol. 2005 Apr 18;3(1):20 [15836792.001]
  • [Cites] Radiother Oncol. 2004 Dec;73(3):313-9 [15588876.001]
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):656-8 [8331240.001]
  • (PMID = 17203356.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Zhang H, Kong Y, Zhang H, He X, Zhang HY, Liu C, Xiao M, Xu X: Leiomyosarcoma of the inferior vena cava: case report and treatment of recurrence with repeat surgery. Ann Vasc Surg; 2010 Apr;24(3):417.e5-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the inferior vena cava: case report and treatment of recurrence with repeat surgery.
  • Leiomyosarcoma of the inferior vena cava (IVC) is an extremely rare malignancy with poor prognosis due to late diagnosis.
  • Surgical resection currently remains the best treatment; however, recurrence frequently occurs and the 5-year survival rate is only 31%.
  • The aim of this study is to report a case of IVC leiomyosarcoma and treatment of recurrence with repeat surgery.
  • A 36-year-old woman with a high-grade leiomyosarcoma originating from the infrahepatic IVC underwent an en bloc excision of the tumor.
  • Since the patient showed no response to adjuvant chemotherapy (i.e., a combination of 5-fluorouracil and gemcitabine), repeat operations were used as the main treatment modality for recurrence.
  • The median time to recurrence was 15 months (range 8-27).
  • Neither complication related to the venous blood flow in the IVC nor renal impairment was noted.
  • Our results suggest that in the setting of chemotherapy-refractory IVC leiomyosarcoma repeat surgery may be an alternative treatment for recurrence and improve survival time.
  • [MeSH-major] Abdominal Neoplasms / surgery. Digestive System Surgical Procedures. Leiomyosarcoma / surgery. Neoplasm Recurrence, Local. Pelvic Neoplasms / surgery. Vascular Neoplasms / surgery. Vascular Surgical Procedures. Vena Cava, Inferior / surgery
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Drug Resistance, Neoplasm. Female. Humans. Reoperation. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20036495.001).
  • [ISSN] 1615-5947
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement